宣泰医药
(688247)
| 流通市值：49.60亿 | | | 总市值：49.60亿 |
| 流通股本：4.53亿 | | | 总股本：4.53亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 219,607,034.66 | 108,926,965.45 | 511,619,303.14 | 362,608,213.87 |
| 营业收入 | 219,607,034.66 | 108,926,965.45 | 511,619,303.14 | 362,608,213.87 |
| 二、营业总成本 | 177,953,022.18 | 88,936,260.56 | 384,024,287.06 | 266,457,899.41 |
| 营业成本 | 129,059,238.3 | 65,435,546.45 | 247,466,984.44 | 176,822,016.82 |
| 税金及附加 | 1,585,056.54 | 860,968.84 | 2,713,038.71 | 1,996,359.69 |
| 销售费用 | 4,419,393.02 | 1,876,787.23 | 10,394,841.26 | 6,836,662.01 |
| 管理费用 | 18,642,446.79 | 8,928,620.49 | 44,854,353.91 | 27,716,639.75 |
| 研发费用 | 25,703,973.68 | 12,449,732.66 | 84,924,730.08 | 56,471,663.02 |
| 财务费用 | -1,457,086.15 | -615,395.11 | -6,329,661.34 | -3,385,441.88 |
| 其中:利息费用 | 652.84 | 164.79 | 2,553.17 | 2,208.77 |
| 其中:利息收入 | 1,831,761.53 | 706,967.93 | 4,330,643.05 | 3,201,812.22 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 6,829,858.09 | 861,541.83 | 12,044,930.79 | 6,995,137.82 |
| 资产减值损失(新) | -1,014,367.59 | -537,368.25 | 1,621,752.05 | 122,816.63 |
| 信用减值损失(新) | 1,697,598.45 | 2,051,750.77 | -3,930,456.51 | -3,420,670.57 |
| 其他收益 | 2,066,744.53 | 984,713.93 | 6,549,067.8 | 2,920,413.33 |
| 四、营业利润 | 51,233,845.96 | 23,351,343.17 | 143,880,310.21 | 102,768,011.67 |
| 加:营业外收入 | 5,486.5 | 4,027.85 | 5,649.23 | 5,549.16 |
| 减:营业外支出 | 213,502.11 | 78,379.44 | 1,803,759.21 | 836,057.54 |
| 五、利润总额 | 51,025,830.35 | 23,276,991.58 | 142,082,200.23 | 101,937,503.29 |
| 减:所得税费用 | 5,440,164.89 | 2,787,682.49 | 14,381,650.06 | 9,364,528.57 |
| 六、净利润 | 45,585,665.46 | 20,489,309.09 | 127,700,550.17 | 92,572,974.72 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 45,585,665.46 | 20,489,309.09 | 127,700,550.17 | 92,572,974.72 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 45,585,665.46 | 20,489,309.09 | 127,700,550.17 | 92,572,974.72 |
| 扣除非经常损益后的净利润 | 39,523,041.49 | 19,067,636.31 | 113,965,967.97 | 85,039,247.1 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.1 | 0.05 | 0.28 | 0.21 |
| (二)稀释每股收益 | 0.1 | 0.05 | 0.28 | 0.21 |
| 八、其他综合收益 | 357.33 | - | 131,292.42 | 10,602.66 |
| 归属于母公司股东的其他综合收益 | 357.33 | - | 131,292.42 | 10,602.66 |
| 九、综合收益总额 | 45,586,022.79 | 20,489,309.09 | 127,831,842.59 | 92,583,577.38 |
| 归属于母公司股东的综合收益总额 | 45,586,022.79 | 20,489,309.09 | 127,831,842.59 | 92,583,577.38 |
| 公告日期 | 2025-08-23 | 2025-04-30 | 2025-04-30 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |